|
Published by: Business Insights
Published: Mar. 1, 2003 - 252 Pages
Table of Contents
Executive Summary
The Biotech sector in the post-genomic era
Chapter 1 Technology Overview
Introduction to the post-genomic era
Structural genomics
Sequencing
Sequencing techniques
Genotyping
SNPs
Techniques to identify, detect and validate SNPs
Association studies
SNP scoring
Pharmacogenomics
Key characteristics of the completed human genome
Protein expression
Gene expression
Abnormal gene expression
Expression profiling
Proteomics
Functional genomics
The gene-to-function approach
The function-to-gene approach
Limitations
Determining a gene function
From the genome to the proteome
Post-translational modification
Transcriptomics
Glycomics
CBPs
Proteomics
Protein functions and disease
Structural proteomics
Protein structures
Mapping the human proteome
Functional proteomics
Protein functions and interactions
Proteins and diseases
Cellomics
Systems biology
The search for disease markers
Bioinformatics
Data management challenges
Bioinformatic software
Chapter 2 Drug Discovery
Traditional and genomics-based drug discovery
Small molecule therapeutics
Market drivers
The product pipeline gap
New and improved drug discovery technologies
The drug discovery process
Target identification
Target validation
Lead generation/primary screening
Lead optimisation
Limitations
Functional genomics in drug discovery
Proteomics in drug discovery
Targeting protein expression
Targeting protein interactions
SNP scoring in drug discovery
Increasing the efficiency of drug discovery
Integrated use of technologies
Chemical genomics
Target identification in the post-genomic era
Novel biological targets
Targeting gene regulation
Gene switches
Apoptosis
Target validation in the post-genomic era
Role of functional genomics
Determining the precise functions of individual genes
Knockout mice
Antisense inhibition assays
Lead generation in the post-genomic era
Ultra-high throughput systems
Lead optimisation in the post-genomic era
Rational drug design in the post-genomic era
Structure-based drug design
Biological-modelling software
DNA sequence data
Combinatorial chemistry
Prediction of safety and efficacy of drugs
Targeting signalling pathways inside the cell
Managing bioinformatics information
Bioinformatic solutions
Commercial exploitation of data
Informational genomics
The merging of bioinformatics and chemoinformatics
Trends in genomics/proteomics databases
Bio-simulation technologies
New bio-simulation in silico tools
Chapter 3 Development of Small Molecule Drugs and Biotherapies
Traditional drug development
Market drivers
The drug development process
Preclinical stage
Drug development in the post-genomic era
Role of pharmacogenomics
SNP scoring
Preclinical testing
Segmented markets and revenue streams for pharmacogenomics-derived products
Computer-based management solutions
Drug delivery advancements
Delivery of biopharmaceuticals
Delivery of therapeutic proteins and peptides
Directed molecular evolution
Non-random mutagenesis
Molecular breeding
Drug development outsourcing industry
A full-service industry
Industry consolidation
New and emerging biotherapies
Protein therapy
Monoclonal antibodies
Antisense therapy
Classes of antisense agents
Exploiting the technology's advantage
Effective drug delivery
DNA vaccines and gene therapy
The challenge of translating sequence data into human vaccines
New applications for gene therapy
Customized gene therapy
Glycotherapy
Major therapy areas
Infectious disease
Cardiovascular disease
Oncology
Chapter 4 Predictive Diagnostics
Overview of the traditional IVD industry
Segmentation
IVDs in the post-genomic era
Predictive diagnostics and preventive medicine
Predisposition tests
Cancer
Cardiovascular disease
Early detection of disease
Genomics and early detection of disease
Infectious disease
Cancer
Proteomics and early detection of disease
Detection of pre-symptomatic disease
The role of the homebrew market
Chapter 5 Theranostics
Drug selection in the post-genomic era
Theranostics and personalized medicine
Theranostics and established drugs
Gene-based theranostics and applications
Infectious disease
Cancer
Cardiovascular disease
Other diseases
Prediction of drug toxicity
Proteomics: the next frontier in theranostics
Impact of bioinformatics
Does theranostics improve outcomes?
Chapter 6 Company Profiles
Introduction
ACADIA Pharmaceuticals Inc
Summary financial data
Company overview
Genomic target discovery
Platform drug discovery technologies
Applications of platform technologies
Drug discovery pipeline
Collaborations
Applera Corp (Celera Genomics business unit)
Summary financial data
Company overview
Applied Biosystems
Celera Genomics
Celera Diagnostics
The Celera Discovery System
Program to discover SNPs in genes
Drug discovery and development
Collaborations
ArQule Inc
Summary financial data
Company overview
Integrated drug discovery platform
AMAP Chemistry Operating System
Drug discovery products and services
Internal drug discovery program
Collaborations
Athersys Inc
Summary financial data
Company overview
RAGE technology
Applications
Collaborations
Cellomics Inc
Summary financial data
Company overview
Core cellomics competencies
Integrated product platform
Cellular screening products
Bioinformatics products
Collaborations
Cytogen Corp
Summary financial data
Company overview
Systems biology approach
Proteomics-based products - ProChart protein pathway database
Protein Arrays
Collaborations
DiagnoSwiss SA
Summary financial data
Company overview
Technology for rapid protein analysis
Microfluidics technology
Lab-on-a-chip systems
Immunoassays on microchip format
Genaissance Pharmaceuticals Inc
Summary financial data
Company overview
HAP technology platform
Informatics technology platform
Applications of HAP technology
HAP drug discovery pipeline
Collaborations
Gene Logic Inc
Summary financial data
Company overview
Gene expression technology
Gene expression databases
Collaborations
Acquisition of TherImmune Research Corporation
Keryx Biopharmaceuticals Inc
Summary financial data
Company overview
KinAce drug discovery technology
Peptide conversion technology
Functional genomics program
KinAce drug discovery pipeline
Lexicon Genetics Inc
Summary financial data
Company overview
The Genome 5000 program
Gene knockout technology
OmniBank library and database
Drug discovery programs
Functional Genomics programs
Collaborations
Lynx Therapeutics Inc
Summary financial data
Company overview
Megaclone technology and applications
Proteomics technology and applications
Internal product development
Collaborations
Myriad Genetics Inc
Summary financial data
Company overview
An integrated proteomics platform
Genomic technologies
Predictive medicine products
Drug discovery pipeline
Collaborations
Neurogen Corporation
Summary financial data
Company overview
Accelerated Intelligent Drug Discovery
Drug discovery pipeline
Collaborations
Orchid BioSciences Inc
Summary financial data
Company overview
SNP-IT SNP scoring technology
Collaborations
Rigel Pharmaceuticals Inc
Summary financial data
Company overview
Combinatorial biology platform
Proteomics program
Drug discovery portfolio
Collaborations
Rosetta Inpharmatics Inc (acquired by Merck & Co.)
Summary financial data
Company overview
Informational genomics platform
Collaborations
Sequenom Inc
Summary financial data
Company overview
MassARRAY genotyping technology
Collaborations
Synaptic Pharmaceutical Corp (acquired by Lundbeck)
Summary financial data
Company overview
Merger with Lundbeck
SNAP drug discovery platform
Collaborations
Vertex Pharmaceuticals Inc
Summary financial data
Company overview
Chemogenomics platform
Drug discovery technologies
Drug discovery pipeline
Collaborations
Chapter 7 Conclusions - Trends and Opportunities
Post-genomic biotechnology is changing medicine
Young companies are driving the changes
The value of post-genomic science to the pharmaceutical industry
Towards personalized and predictive medicine
Using pharmacogenomics throughout the drug lifecycle?
Issues preventing dissemination of personal genetic information
Benefits of orphan-drug status
Analysis of multiple gene and/or protein expression
Drug discovery in transition
New targets for drug discovery
Tackling the critical issue of productivity
Novel drug discovery technologies
Integration and collaboration are key
Is personalized medicine the answer to falling R&D productivity?
The potential of post-genomic science
Role of alliances in drug discovery
Post-genomic outsourcing industry
Business models in bioinformatics
In-house versus external investment
IT giants enter the life science market
Prominet failures
The limitations of only selling bioinformatics tools
Acquisitions
IP issues in the post-genomic era
Mining the proteome
IP as a restrictor of development
Alternative approaches to overcome IP barriers
Key trends in the pharmacogenomics industry until 2012
Chapter 8 Appendix
Terms and abbreviations
Index of companies/organisations included in the report
List of Figures
Figure 1.1: Types of data analysis involved in the identification of biological targets for drugs or diagnostics
Figure 3.2: Using market-driven genotype screening to increase the revenue potential of pharmacogenomics-derived products
Figure 7.3: Selected niche technologies and providers that are expected to impact on discovery and development of genomic-based drugs
Figure 7.4: The link between personalized medicine and R&D productivity
Figure 7.5: Key events and effects impacting the genomics industry until 2012
List of Tables
Table 3.1: World pharmaceutical market by regions
Table 3.2: World pharmaceutical market by therapeutic category
Table 6.3: Summary financial data for ACADIA Pharmaceuticals Inc, 2000-2002
Table 6.4: Summary financial data for Applera Corp, 2000-2002
Table 6.5: Summary financial data for ArQule Inc, 2000-2002
Table 6.6: Summary financial data for Athersys Inc
Table 6.7: Summary financial data for Cellomics Inc
Table 6.8: Summary financial data for Cytogen Corp, 2000-2002
Table 6.9: Summary financial data for Genaissance Pharmaceuticals Inc, 2000-2002
Table 6.10: Summary financial data for Gene Logic Inc, 2000-2002
Table 6.11: Summary financial data for Keryx Biopharmaceuticals Inc, 2000-2002
Table 6.12: Summary financial data for Lexicon Genetics Inc, 2000-2002
Table 6.13: Summary financial data for Lynx Therapeutics Inc, 2000-2002
Table 6.14: Summary financial data for Myriad Genetics Inc, 2000-2002
Table 6.15: Summary financial data for Neurogen Corporation
Table 6.16: Summary financial data for Orchid Biosciences Inc, 2000-2002
Table 6.17: Summary financial data for Rigel Pharmaceuticals Inc, 2000-2002
Table 6.18: Summary financial data for Rosetta Inpharmatics, 1998-2000
Table 6.19: Summary financial data for Sequenom Inc, 2000-2002
Table 6.20: Summary financial data for Synaptic Pharmaceutical Corp, 2000-2002
Table 6.21: Summary financial data for Vertex Pharmaceuticals Inc, 2000-2002
AbstractAn important milestone in the genomic era was reached in February 2001, when the Human Genome Project and Celera Genomics presented the initial sequencing and analysis of the human genome. Biotechnology in the post-genomic era looks set to change the way in which medicine is practiced, as well as the way in which drugs and diagnostics are discovered and developed. Many exciting and fast-evolving technological advances are being employed to transform the raw sequence data into new treatments and diagnostics. ‘The Outlook for the Biotech Sector in the Post-Genomic Era: Strategies for drug discovery, diagnostics and personalized medicine’, explores the impact of genomics, transcriptomics and proteomics and identifies both scientific and commercial opportunities in genomic technology. As the focus of drug development in post-genomic markets shifts towards preventive and personalized medicine, this report analyzes the allocation of research resources and identifies where the greatest return on R&D investment may be achieved. As a decision-making support, this report will enable pharma and biotech executives to act quickly in securing a competitive edge.
Get Full Details About This Report >>
|
